Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor

Executive Summary

J&J subsidiary will pay up to $50 mil. for 3-Dimensional Pharmaceuticals' orally active direct thrombin inhibitor program. Centocor will make a cash payment of $6 mil. up front, with up to an additional $44 mil. in milestone payments for the first compound marketed. 3DP will receive additional milestone payments on future products and royalties on the sale of any product marketed under the agreement. 3DP retains an option to co-develop and co-promote the deep vein thrombosis indication. The firm's leading anticoagulant compound, 3DP-4815, is in Phase I trials. 3DP's agreement with Wyeth-Ayerst for the same thrombin inhibitor technology was terminated in June 1999
Advertisement

Related Content

J&J Adds New Dimension To Drug Discovery Efforts With 3DP Acquisition
J&J Adds New Dimension To Drug Discovery Efforts With 3DP Acquisition
Advertisement
UsernamePublicRestriction

Register

PS037130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel